Exact Mass: 283.1685

Exact Mass Matches: 283.1685

Found 80 metabolites which its exact mass value is equals to given mass value 283.1685, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Amabiline

(7aS)-2,3,5,7a-tetrahydro-1H-pyrrolizin-7-ylmethyl (2S)-2-hydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO4 (283.1783)


Amabiline belongs to alkaloids and derivatives class of compounds. Those are naturally occurring chemical compounds that contain mostly basic nitrogen atoms. This group also includes some related compounds with neutral and even weakly acidic propertiesand is also some synthetic compounds of similar structure are attributed to alkaloids. In addition to carbon, hydrogen and nitrogen, alkaloids may also contain oxygen, sulfur and more rarely other elements such as chlorine, bromine, and phosphorus. Amabiline is soluble (in water) and a very weakly acidic compound (based on its pKa). Amabiline can be found in borage, which makes amabiline a potential biomarker for the consumption of this food product.

   

Supinine

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1H-pyrrolizin-7-yl)methyl ester, (7aS-(7(2R*,3S*),7aR*))-

C15H25NO4 (283.1783)


Supinine is also known as spinin. Supinine is soluble (in water) and a very weakly acidic compound (based on its pKa). Supinine can be found in borage, which makes supinine a potential biomarker for the consumption of this food product.

   

alpha-Hydroxymetoprolol

1-[4-(1-hydroxy-2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol

C15H25NO4 (283.1783)


alpha-Hydroxymetoprolol is a metabolite of metoprolol. Metoprolol is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension. The active substance metoprolol is employed either as metoprolol succinate or metoprolol tartrate (where 100 mg metoprolol tartrate corresponds to 95 mg metoprolol succinate). The tartrate is an immediate-release and the succinate is an extended-release formulation. (Wikipedia)

   

Lysylhistidine

(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(1H-imidazol-5-yl)propanoic acid

C12H21N5O3 (283.1644)


Lysylhistidine is a dipeptide composed of lysine and histidine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Histidyllysine

(2S)-6-amino-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]hexanoic acid

C12H21N5O3 (283.1644)


Histidyllysine is a dipeptide composed of histidine and lysine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Cadralazine

N-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}ethoxycarbohydrazonic acid

C12H21N5O3 (283.1644)


C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DB - Hydrazinophthalazine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent Cadralazine is an antihypertensive of the hydrazinophthalazine chemical class. D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

Octa-2,6-dienoylcarnitine

3-(octa-2,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


octa-2,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an octa-2,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-2,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-2,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-3,6-dienoylcarnitine

3-(octa-3,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


octa-3,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an octa-3,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(4Z,6Z)-Octa-4,6-dienoylcarnitine

3-(octa-4,6-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


(4Z,6Z)-octa-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,6Z)-octa-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,6Z)-octa-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4Z,6Z)-octa-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-2,5-dienoylcarnitine

3-(octa-2,5-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


octa-2,5-dienoylcarnitine is an acylcarnitine. More specifically, it is an octa-2,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-2,5-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-2,5-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-2,4-dienoylcarnitine

3-(octa-2,4-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


octa-2,4-dienoylcarnitine is an acylcarnitine. More specifically, it is an octa-2,4-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-2,4-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-2,4-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Octa-3,5-dienoylcarnitine

3-(octa-3,5-dienoyloxy)-4-(trimethylazaniumyl)butanoate

C15H25NO4 (283.1783)


octa-3,5-dienoylcarnitine is an acylcarnitine. More specifically, it is an octa-3,5-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,5-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,5-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Atglistatin

1-[4-(dimethylamino)-[1,1-biphenyl]-3-yl]-3,3-dimethylurea

C17H21N3O (283.1685)


Atglistatin is a selective adipose triglyceride lipase (ATGL) inhibitor which inhibits lipolysis with an IC50 of 0.7 μM in vitro.

   

Histidinyl-Lysine

6-Amino-2-{[2-amino-1-hydroxy-3-(1H-imidazol-5-yl)propylidene]amino}hexanoate

C12H21N5O3 (283.1644)


   

Aerocyanidin

(-)-Aerocyanidin

C15H25NO4 (283.1783)


   
   

Oprea1_017285

Oprea1_017285

C17H21N3O (283.1685)


   

N1-(5,6-Dimethyl-2,3-dihydro-1H-benzo[d]imidazol-2-yliden)oct-2-ynamide

N1-(5,6-Dimethyl-2,3-dihydro-1H-benzo[d]imidazol-2-yliden)oct-2-ynamide

C17H21N3O (283.1685)


   

1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione

NCGC00380136-01!1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione

C15H25NO4 (283.1783)


   

1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione [IIN-based on: CCMSLIB00000846771]

NCGC00380136-01!1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione [IIN-based on: CCMSLIB00000846771]

C15H25NO4 (283.1783)


   

1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione [IIN-based: Match]

NCGC00380136-01!1-(2,3-dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione [IIN-based: Match]

C15H25NO4 (283.1783)


   

3-oxo-C11-HSL

3-oxo-C11-HSL

C15H25NO4 (283.1783)


   

UNII:C19D0413EL

α-Hydroxymetoprolol

C15H25NO4 (283.1783)


   
   
   

His-lys

2-(2,6-diaminohexanamido)-3-(1H-imidazol-5-yl)propanoic acid

C12H21N5O3 (283.1644)


A dipeptide formed from L-histidine and L-lysine residues.

   

Lys-his

6-amino-2-[2-amino-3-(1H-imidazol-5-yl)propanamido]hexanoic acid

C12H21N5O3 (283.1644)


   

Cadralazine

N-{6-[ethyl(2-hydroxypropyl)amino]pyridazin-3-yl}ethoxycarbohydrazonic acid

C12H21N5O3 (283.1644)


C - Cardiovascular system > C02 - Antihypertensives > C02D - Arteriolar smooth muscle, agents acting on > C02DB - Hydrazinophthalazine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

1-BOC-4-(4-METHOXY-4-OXO-2-BUTENYL)PIPERIDINE

1-BOC-4-(4-METHOXY-4-OXO-2-BUTENYL)PIPERIDINE

C15H25NO4 (283.1783)


   

cis-2-Benzylaminomethyl-1-cyclooctanol hydrochloride

cis-2-Benzylaminomethyl-1-cyclooctanol hydrochloride

C16H26ClNO (283.1703)


   

1-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclobutanecarbonitrile

1-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-cyclobutanecarbonitrile

C17H22BNO2 (283.1744)


   

(2-(4-METHYL-2-PHENYLPIPERAZIN-1-YL)PYRIDIN-3-YL)METHANOL

(2-(4-METHYL-2-PHENYLPIPERAZIN-1-YL)PYRIDIN-3-YL)METHANOL

C17H21N3O (283.1685)


   

2-(TERT-BUTOXYCARBONYL)DECAHYDROISOQUINOLINE-6-CARBOXYLIC ACID

2-(TERT-BUTOXYCARBONYL)DECAHYDROISOQUINOLINE-6-CARBOXYLIC ACID

C15H25NO4 (283.1783)


   

5-((tert-Butyldimethylsilyloxy)methyl)-2,3-dimethoxypyridine

5-((tert-Butyldimethylsilyloxy)methyl)-2,3-dimethoxypyridine

C14H25NO3Si (283.1604)


   

1-Tert-Butyl 4-Methyl 4-Allylpiperidine-1,4-Dicarboxylate

1-Tert-Butyl 4-Methyl 4-Allylpiperidine-1,4-Dicarboxylate

C15H25NO4 (283.1783)


   

tert-butyl 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopent-3-ene-1-carboxylate

tert-butyl 1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclopent-3-ene-1-carboxylate

C15H25NO4 (283.1783)


   

6-((tert-Butyldimethylsilyloxy)methyl)-2,3-dimethoxypyridine

6-((tert-Butyldimethylsilyloxy)methyl)-2,3-dimethoxypyridine

C14H25NO3Si (283.1604)


   

Uracil,6-amino-5-(2-diethylaminoacetamido)-1,3-dimethyl- (6CI)

Uracil,6-amino-5-(2-diethylaminoacetamido)-1,3-dimethyl- (6CI)

C12H21N5O3 (283.1644)


   
   

Methyl 1-Boc-3-allylpiperidine-3-carboxylate

Methyl 1-Boc-3-allylpiperidine-3-carboxylate

C15H25NO4 (283.1783)


   

2,4,6-TRIISOPROPYLBENZENESULFONAMIDE

2,4,6-TRIISOPROPYLBENZENESULFONAMIDE

C15H25NO2S (283.1606)


   

2-(4-Methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol

2-(4-Methyl-2-phenyl-1-piperazinyl)-3-pyridinemethanol

C17H21N3O (283.1685)


   

(S)-Ethyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate

(S)-Ethyl 1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carboxylate

C15H25NO4 (283.1783)


   

2-Methyl-2-propanyl 3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]decan e-7-carboxylate

2-Methyl-2-propanyl 3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]decan e-7-carboxylate

C15H25NO4 (283.1783)


   

1-(4-Aminophenyl)-4-(4-methoxyphenyl)piperazine

1-(4-Aminophenyl)-4-(4-methoxyphenyl)piperazine

C17H21N3O (283.1685)


   

methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate

methyl 4-((tert-butoxycarbonyl)amino)bicyclo[2.2.2]octane-1-carboxylate

C15H25NO4 (283.1783)


   

N-cyclopentyl-5-(4-methoxyphenyl)-2-methylpyrimidin-4-amine

N-cyclopentyl-5-(4-methoxyphenyl)-2-methylpyrimidin-4-amine

C17H21N3O (283.1685)


   

2-[(tert-butoxy)carbonyl]-2-azaspiro[4.5]decane-7-carboxylic acid

2-[(tert-butoxy)carbonyl]-2-azaspiro[4.5]decane-7-carboxylic acid

C15H25NO4 (283.1783)


   

ETHYL (2Z)-3-AMINO-4,4,4-TRICHLORO-2-CYANOBUT-2-ENOATE

ETHYL (2Z)-3-AMINO-4,4,4-TRICHLORO-2-CYANOBUT-2-ENOATE

C15H25NO4 (283.1783)


   

(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate

(E)-tert-Butyl 4-(2-ethoxy-2-oxoethylidene)azepane-1-carboxylate

C15H25NO4 (283.1783)


   

ethyl 6-{[(tert-butoxy)carbonyl]amino}spiro[3.3]heptane-2-carboxylate

ethyl 6-{[(tert-butoxy)carbonyl]amino}spiro[3.3]heptane-2-carboxylate

C15H25NO4 (283.1783)


   

Oxtriphylline

choline thieophyllinate

C12H21N5O3 (283.1644)


R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DA - Xanthines D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor

   

3-Oxo-N-[(3S)-2-oxooxolan-3-yl]undecanamide

3-Oxo-N-[(3S)-2-oxooxolan-3-yl]undecanamide

C15H25NO4 (283.1783)


   

1-(2-(3-Cyclohexenyl)ethyl)silatrane

1-(2-(3-Cyclohexenyl)ethyl)silatrane

C14H25NO3Si (283.1604)


   

N-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-L-glutamic acid

N-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-L-glutamic acid

C15H25NO4 (283.1783)


   

Octa-2,6-dienoylcarnitine

Octa-2,6-dienoylcarnitine

C15H25NO4 (283.1783)


   

Octa-3,6-dienoylcarnitine

Octa-3,6-dienoylcarnitine

C15H25NO4 (283.1783)


   

Octa-2,5-dienoylcarnitine

Octa-2,5-dienoylcarnitine

C15H25NO4 (283.1783)


   

Octa-2,4-dienoylcarnitine

Octa-2,4-dienoylcarnitine

C15H25NO4 (283.1783)


   

Octa-3,5-dienoylcarnitine

Octa-3,5-dienoylcarnitine

C15H25NO4 (283.1783)


   

(4Z,6Z)-Octa-4,6-dienoylcarnitine

(4Z,6Z)-Octa-4,6-dienoylcarnitine

C15H25NO4 (283.1783)


   

[(8R)-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2R)-2-hydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

[(8R)-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl (2R)-2-hydroxy-2-[(1S)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO4 (283.1783)


   

1-[4-(Diethylamino)phenyl]-3-phenylurea

1-[4-(Diethylamino)phenyl]-3-phenylurea

C17H21N3O (283.1685)


   

N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide

N-tert-butyl-7,7-dimethyl-2-oxo-1,8-dioxaspiro[4.5]decane-4-carboxamide

C15H25NO4 (283.1783)


   

1-(2,3-Dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione

1-(2,3-Dihydropyrrol-1-yl)-8,9-dihydroxy-2-methyldecane-1,3-dione

C15H25NO4 (283.1783)


   

11-Cyclohexyl-12-oxa-1,8,11-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-2,4,6,8-tetraene

11-Cyclohexyl-12-oxa-1,8,11-triazatetracyclo[7.6.0.02,7.010,14]pentadeca-2,4,6,8-tetraene

C17H21N3O (283.1685)


   

N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)-2-(propan-2-ylamino)acetamide

N-(2,3-dihydro-1H-cyclopenta[b]quinolin-9-yl)-2-(propan-2-ylamino)acetamide

C17H21N3O (283.1685)


   

1-(2,5-Dimethoxyphenyl)-1-[(trimethylsilyl)oxy]propan-2-amine

1-(2,5-Dimethoxyphenyl)-1-[(trimethylsilyl)oxy]propan-2-amine

C14H25NO3Si (283.1604)


   
   

Amabiline

Butanoic acid, 2,3-dihydroxy-2-(1-methylethyl)-, (2,3,5,7a-tetrahydro-1H-pyrrolidizin-7-yl)methyl ester

C15H25NO4 (283.1783)


A carboxylic ester obtained by formal condensation of the carboxy group of (2S,3S)-2,3-dihydroxy-2-isopropylbutanoic acid with the hydroxy group of (7aS)-2,3,5,7a-tetrahydropyrrolizin-7-ylmethanol.

   
   

(7ar)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

(7ar)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H25NO4 (283.1783)


   

2-ethyl-3-[2-(1h-indol-3-yl)ethyl]-2,5-dimethylimidazol-4-one

2-ethyl-3-[2-(1h-indol-3-yl)ethyl]-2,5-dimethylimidazol-4-one

C17H21N3O (283.1685)


   

(1s,2r,4ar,5r)-8-isopropyl-2,5-dimethyl-5-(sulfanylideneamino)-1,3,4,4a,6,7-hexahydronaphthalene-1,2-diol

(1s,2r,4ar,5r)-8-isopropyl-2,5-dimethyl-5-(sulfanylideneamino)-1,3,4,4a,6,7-hexahydronaphthalene-1,2-diol

C15H25NO2S (283.1606)


   

(1s,4r,4ar,7r)-1-isopropyl-4,7-dimethyl-4-(sulfanylideneamino)-3,4a,5,6-tetrahydro-2h-naphthalene-1,7-diol

(1s,4r,4ar,7r)-1-isopropyl-4,7-dimethyl-4-(sulfanylideneamino)-3,4a,5,6-tetrahydro-2h-naphthalene-1,7-diol

C15H25NO2S (283.1606)


   

3-(10-carbonoperoxoyldecyl)-2-isocyano-2-methyloxirane

3-(10-carbonoperoxoyldecyl)-2-isocyano-2-methyloxirane

C15H25NO4 (283.1783)


   

(1s,4s,4ar,7s)-1-isopropyl-4,7-dimethyl-4-(sulfanylideneamino)-3,4a,5,6-tetrahydro-2h-naphthalene-1,7-diol

(1s,4s,4ar,7s)-1-isopropyl-4,7-dimethyl-4-(sulfanylideneamino)-3,4a,5,6-tetrahydro-2h-naphthalene-1,7-diol

C15H25NO2S (283.1606)


   

[(1r,7as)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2,3-dimethylbutanoate

[(1r,7as)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2,3-dimethylbutanoate

C15H25NO4 (283.1783)


   

(2r,3r)-3-[(1r)-10-carboxy-1-hydroxydecyl]-2-isocyano-2-methyloxirane

(2r,3r)-3-[(1r)-10-carboxy-1-hydroxydecyl]-2-isocyano-2-methyloxirane

C15H25NO4 (283.1783)


   

5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-isopropylbutanoate

5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-isopropylbutanoate

C15H25NO4 (283.1783)